Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Return on Capital Employed (2016 - 2026)

Heron Therapeutics filings provide 14 years of Return on Capital Employed readings, the most recent being 6.51% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 406.0% to 6.51% in Q1 2026 year-over-year; TTM through Mar 2026 was 6.51%, a 406.0% decrease, with the full-year FY2025 number at 1.71%, up 674.0% from a year prior.
  • Return on Capital Employed hit 6.51% in Q1 2026 for Heron Therapeutics, down from 1.62% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 1.06% in Q3 2025 to a low of 145.75% in Q2 2022.
  • Median Return on Capital Employed over the past 5 years was 56.86% (2024), compared with a mean of 58.02%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -6142bps in 2022 and later surged 7706bps in 2024.
  • Heron Therapeutics' Return on Capital Employed stood at 97.52% in 2022, then rose by 22bps to 75.68% in 2023, then surged by 89bps to 8.51% in 2024, then surged by 81bps to 1.62% in 2025, then crashed by -301bps to 6.51% in 2026.
  • The last three reported values for Return on Capital Employed were 6.51% (Q1 2026), 1.62% (Q4 2025), and 1.06% (Q3 2025) per Business Quant data.